Blood:EGFR依赖性的DNA修复促进造血再生

2020-05-13 QQY MedSci原创

EGF通过激活DNA-PKcs和NHEJ促进HSC DNA修复和造血再生。 EGF在化疗后驱动造血细胞再生,并在放疗后促进人HSC恢复,同时增加HSC基因间突变

化疗和放疗可引起造血干细胞(HSCs)DNA损伤,导致HSC耗竭和功能失调,并随着时间的推移发生恶性转化。HSC DNA修复的外在调节尚不未完全清楚,骨髓抑制后增强HSC DNA修复的疗法也尚不成熟。

近期,Fang等人发现表皮生长因子受体(EGFR)通过激活DNA依赖性蛋白激酶-催化亚基(DNA-PKcs)和非同源末端连接(NHEJ)来调节HSC的DNA修复。全身放疗(TBI)后体内的造血再生取决于EGF通过激活DNA-PKcs介导的DNA损伤修复。

条件性敲除造血干/祖细胞(HSPC)中的EGFR会大大降低放疗后DNA-PKcs的活性,导致HSC DNA损伤增加,抑制HSC恢复。予以EGF可促进化疗小鼠的HSC DNA修复和血液的快速恢复,且对体内AML的生长没有影响。

此外,EGF治疗还可促进体内能够在辐射损伤后在重新分化的多谱系人HSC的恢复。

全基因组测序分析显示,用EGF处理的小鼠的HSPC的编码区突变没有增加,但基因间的拷贝数变异增多。

综上所述,本研究结果表明EGF通过增强NHEJ促进体内HSC DNA修复和造血再生。EGF具有促进人造血细胞再生的治疗潜能,因此,有必要进一步研究以评估其长期造血作用。

原始出处:

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1494731, encodeId=bb231494e3193, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533730, encodeId=f3761533e3064, content=<a href='/topic/show?id=b1b260e6fb' target=_blank style='color:#2F92EE;'>#DNA修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6076, encryptionId=b1b260e6fb, topicName=DNA修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f12479618, createdName=jambiya, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534505, encodeId=16901534505f6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-15 俅侠
  2. [GetPortalCommentsPageByObjectIdResponse(id=1494731, encodeId=bb231494e3193, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533730, encodeId=f3761533e3064, content=<a href='/topic/show?id=b1b260e6fb' target=_blank style='color:#2F92EE;'>#DNA修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6076, encryptionId=b1b260e6fb, topicName=DNA修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f12479618, createdName=jambiya, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534505, encodeId=16901534505f6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-15 jambiya
  3. [GetPortalCommentsPageByObjectIdResponse(id=1494731, encodeId=bb231494e3193, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533730, encodeId=f3761533e3064, content=<a href='/topic/show?id=b1b260e6fb' target=_blank style='color:#2F92EE;'>#DNA修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6076, encryptionId=b1b260e6fb, topicName=DNA修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff6f12479618, createdName=jambiya, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534505, encodeId=16901534505f6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Fri May 15 10:56:06 CST 2020, time=2020-05-15, status=1, ipAttribution=)]
    2020-05-15 liuyiping

相关威廉亚洲官网

J Clin Oncol:局部前列腺癌的常规分割放疗和中度低分割放疗比较

之前发表的单中心随机前瞻性实验并没有表现出中度低分割强度调节放疗(H-IMRT)比常规的分割IMRT(C-IMRT)在5年生化和/或临床疾病失败(BCDF)中具有优越性。最近,有研究人员使用新的风险组

Blood:既往20余年结节性淋巴细胞为主型霍奇金淋巴瘤的治疗预后

以RT/CMT作为I-II期NLPHL患者的前期治疗或可提高患者的PFS。

Cell Death Dis:纤溶酶原可促进放射性损伤伤口愈合

放射性治疗作为各种肿瘤的重要治疗手段,对于非癌性的正常组织往往具有剂量限制性的病理效应。组织对辐射的敏感性取决于分裂细胞的数量。因此,具有较高增殖能力的正常组织(例如皮肤)受放射治疗的影响更为严重。

Radiother Oncol:中风险和高风险前列腺癌多中心II期hypo-FLAME试验的主要终点分析

前列腺癌(PCa)放疗后的局部复发常发生在肉眼可见的肿瘤部位。由于PCa细胞对高剂量敏感,低分割全腺体立体定向体放射治疗(SBRT)同时结合前列腺内宏观肿瘤(s)消融微烧蚀可能是降低局部失败风险的一种

BMC Cancer:根治性前列腺切除术后高危PSA复发的前列腺癌的抢救性放疗加安慰剂与SRT加恩扎鲁胺的II期随机双盲对照研究

在前列腺癌根治性切除术后PSA升高的男性中,抢救性放射治疗(SRT)提供了第二次治愈机会。激素治疗可以与SRT结合使用,以增加对前列腺肿瘤的控制,尽管伴随有更高的治疗副作用率。本试验研究了SRT与激素

Lancet:早期乳腺癌术后1周26Gy放疗方案效果评估

对于早期乳腺癌术后接受局部辅助放疗患者,采用1周以上,5次,总计26Gy的放疗方案对疾病的控制效果与传统的3周以上,15次,总计40Gy放疗方案相当